Trial shows improvements in several clinical outcomes for men with intermediate-risk prostate cancer

Results from the phase 3 NRG Oncology RTOG 0815 clinical study comparing dose-escalated radiotherapy (RT) alone to dose-escalated RT with short-term androgen deprivation (STAD) did not meet its primary endpoint of improving overall survival for men with intermediate-risk prostate cancer through the addition of STAD.

Leave A Comment

Your email address will not be published. Required fields are marked *